Drug repurposing in colorectal cancer by using transcriptomic data
[ X ]
Tarih
2021
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Adana Alparslan Türkeş Bilim ve Teknoloji Üniversitesi
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Kolorektal kanser (KRK), dünya çapında insanların maruz kaldığı en ölümcül kanser türlerinden biridir. Bu çalışmada, ilaç yeniden kullanımı (ilaç reposisyonu) olarak bilinen çok popüler bir yaklaşım ve hesaplamalı biyoloji yöntemleri ile KRK tedavisinde kullanılabilecek aday ilaçları ortaya çıkarmayı amaçladık. İlk olarak, transkriptomik verilerin analiziyle KRK'de ifadesi farklılaşan genler tanımlandı. Daha sonra, farklılaşarak birlikte ifade edilen gen modülleri tanımlandı ve bu modül genlerinin CRC'deki prognostik önemi gösterildi. Son olarak ortaya çıkardığımız gen modüllerine dayanarak, KRK'nin seyrini değiştirebilecek tedavi adayları belirlendi. Bu adaylar, tümör büyümesi üzerindeki etkilerini göstermek için deneysel/klinik çalışmalarda incelenen veya KRK tedavisinde orijinal olarak kullanılmayan/incelenmeyen ilaçları veya küçük molekülleri içerir. Çalışmamızda, yirmi iki genden oluşan KRK'de yeni, farklı şekilde birlikte ifade edilmiş, yüksek oranda birbirine bağlı ve birlikte düzenlenmiş prognostik bir gen modülü ortaya çıkardık. Gallik asit, valinomisin, sisteamin, AZD8055, BRD-K81473043, tirfostin AG1478, BRD-A17065207, dovitinib, trametinib, HDAC6 inhibitor ISOX, AS605240, 480743.cdx, BRD-K03829970, L-6307 ve NVP-TAE684'den oluşan on beş adet ilaç veya molekülü KRK için yeniden kullanım adayı olarak öneriyoruz. HDAC6 inhibitor ISOX, AS605240, 480743.cdx, BRD-K03829970, L6307 ve NVP-TAE684'ü CRC tümörijenezi üzerindeki anti-kanserojen etkileri araştırılmamış yeni yeniden kullanım adayları olarak sunuyoruz. Bulgularımızın klinik olarak araştırılması, KRK için yeni tedavi seçenekleri oluşturması açısından önemlidir. Anahtar Kelimeler: kolorektal kanser, ilaç yeniden kullanımı, transkriptomik veri
Colorectal cancer (CRC) is one of the most fatal cancer types that people suffer from worldwide. In this study, we aimed to reveal the candidate drugs that may be usable in the treatment of CRC via a very popular approach known as drug repurposing (drug repositioning) and computational biology methods. Firstly, differentially expressed genes (DEGs) were identified in CRC via analyzing transcriptomic data. Then, differentially coexpressed gene modules were identified and prognostic significance of these module genes in CRC was demonstrated. Finally, based on the gene modules we uncovered, various treatment candidates that may alter the course of CRC were identified. These candidates include drugs or small molecules which were studied in experimental/clinical studies to demonstrate the effects on tumor growth or not used/studied originally in the treatment of CRC. In our study, we revealed a novel, differentially co-expressed, highly interconnected, and co-regulated prognostic gene module in CRC consisting of twenty two genes. We suggest fifteen drugs or small molecules comprising gallic acid, valinomycin, cysteamine, AZD8055, BRDK81473043, tyrphostin AG1478, BRD-A17065207, dovitinib, trametinib, HDAC6 inhibitor ISOX, AS605240, 480743.cdx, BRD-K03829970, L-6307 and NVP-TAE684 as repurposing candidates for CRC. We present HDAC6 inhibitor ISOX, AS605240, 480743.cdx, BRDK03829970, L-6307, and NVP-TAE684 as novel repuposing candidates whose anticarcinogenic effects on CRC tumorigenesis have not been investigated before. Clinical investigation of our findings is important in terms of creating new treatment options for CRC. Keywords: colorectal cancer, drug repurposing, transcriptomic data
Colorectal cancer (CRC) is one of the most fatal cancer types that people suffer from worldwide. In this study, we aimed to reveal the candidate drugs that may be usable in the treatment of CRC via a very popular approach known as drug repurposing (drug repositioning) and computational biology methods. Firstly, differentially expressed genes (DEGs) were identified in CRC via analyzing transcriptomic data. Then, differentially coexpressed gene modules were identified and prognostic significance of these module genes in CRC was demonstrated. Finally, based on the gene modules we uncovered, various treatment candidates that may alter the course of CRC were identified. These candidates include drugs or small molecules which were studied in experimental/clinical studies to demonstrate the effects on tumor growth or not used/studied originally in the treatment of CRC. In our study, we revealed a novel, differentially co-expressed, highly interconnected, and co-regulated prognostic gene module in CRC consisting of twenty two genes. We suggest fifteen drugs or small molecules comprising gallic acid, valinomycin, cysteamine, AZD8055, BRDK81473043, tyrphostin AG1478, BRD-A17065207, dovitinib, trametinib, HDAC6 inhibitor ISOX, AS605240, 480743.cdx, BRD-K03829970, L-6307 and NVP-TAE684 as repurposing candidates for CRC. We present HDAC6 inhibitor ISOX, AS605240, 480743.cdx, BRDK03829970, L-6307, and NVP-TAE684 as novel repuposing candidates whose anticarcinogenic effects on CRC tumorigenesis have not been investigated before. Clinical investigation of our findings is important in terms of creating new treatment options for CRC. Keywords: colorectal cancer, drug repurposing, transcriptomic data
Açıklama
Fen Bilimleri Enstitüsü, Biyomühendislik Ana Bilim Dalı
Anahtar Kelimeler
Biyomühendislik, Bioengineering
